Enhertu approved for PBS for those with HER2 metastatic breast cancer
09 Nov 2023
BCNA supported the process for Enhertu to be considered for listing on the PBS and we welcome the government subsidy for this exciting new drug.
“This is a significant step towards achieving greater equity of access for a life prolonging drug like Enhertu,” says BCNA director Policy, Advocacy & Support Services Vicki Durston.
Enhertu is listed on the PBS to treat patients who have been diagnosed with metastatic human epidermal growth factor receptor 2 (HER2) positive breast cancer as of 1 November.
Read about the Australian Government’s announcement of the listing of Enhertu on the PBS here.
If you have any questions about Enhertu we encourage you to speak to your treating team.
Categories
- MBS
- PBS
- The Department Of Health And Aged Care
- RACGP
- NIP
- AHPRA
- NSW Health
- Queensland Health
- Victoria Health
- Tasmania News
- Western Australia
- SA Health
- NT HEALTH
- Pharmacy Board Of Ahpra
- National Asthma Council
- NT
- AMA
- NACCHO
- BCNA
- Australian College Of Nurse Practitioners
- Asthma Australia
- LFA
- Palliative Care
- Primary Health Network
- AIHW
- Children's Health Queenland
- Kidney Health
- CHF
- MHC
- Gold Coast
- Tsa
- TGA
- Medicine Shortage
Popular Posts
Tags
- Environmental health National Health and Climate Strategy environmental-health-national-health-and-climate-strategy
